Physician profile
Jonathan S Cross
NPI 1336146927
$46,125.28
in general payments reported to CMS, 2019-2025
66 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $208 · 2021: $352 · 2022: $4,340 · 2023: $6,947 · 2024: $4,504 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $15K · Travel and Lodging: $6,952 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,348.00 |
| Food and Beverage | $15,405.14 |
| Travel and Lodging | $6,951.77 |
| Education | $205.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,194.39 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Eisai INC. | $8,640.73 | 2022-2025 | |
| Argenx US, INC. | $6,132.44 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $2,521.16 | 2021-2025 | Leqembi, Vumerity, Tysabri |
| Pfizer INC. | $2,357.01 | 2023-2025 | |
| Abbott Laboratories | $2,149.87 | 2023-2025 | Infinity, Proclaim, Eterna |
| Ucb, INC. | $2,019.12 | 2022-2025 | Briviact, Nayzilam, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $1,221.05 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Emd Serono, INC. | $1,173.56 | 2022-2025 | Mavenclad, Mavenclad |
| Ipsen Innovation | $1,042.00 | 2023 | Dysport |
| Mdd US Operations, LLC | $786.39 | 2022-2025 | Apokyn |
| Neurocrine Biosciences, INC. | $664.75 | 2022-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $631.75 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $557.72 | 2022-2025 | Vyepti, Rexulti |
| Ge Healthcare | $508.01 | 2019-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $431.84 | 2022-2025 | |
| Lilly USA, LLC | $403.29 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Otsuka America Pharmaceutical, INC. | $397.41 | 2023-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $270.98 | 2020-2025 | Nuplazid |
| Tanabe Pharma America, INC. | $256.46 | 2022-2025 | Radicava |
| Novartis Pharmaceuticals Corporation | $250.69 | 2022-2025 | |
| Janssen Biotech, INC. | $223.88 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $222.28 | 2024-2025 | Wainua |
| Kyowa Kirin, INC. | $215.88 | 2024 | Nourianz |
| Jazz Pharmaceuticals INC. | $184.39 | 2022 | |
| Acorda Therapeutics, INC | $182.30 | 2022-2024 | Inbrija, Ampyra |
| Upsher-Smith Laboratories LLC | $176.23 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $172.79 | 2022-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Avion Pharmaceuticals | $151.32 | 2022-2023 | Dhivy |
| Idorsia Pharmaceuticals US INC | $138.61 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $136.04 | 2022 | |
| Allergan, INC. | $133.30 | 2020-2021 | |
| Novo Nordisk INC | $121.63 | 2025 | |
| Genzyme Corporation | $113.71 | 2023 | |
| Csl Behring | $96.21 | 2024 | Hizentra |
| Neurelis, INC. | $88.29 | 2022-2024 | Valtoco |
| Livanova USA, INC. | $86.21 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Merz Pharmaceuticals, LLC | $85.24 | 2023-2025 | Xeomin |
| Axsome Therapeutics, INC. | $81.95 | 2025 | Symbravo |
| Amgen INC. | $81.20 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $78.62 | 2023-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Sunovion Pharmaceuticals INC. | $77.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $73.89 | 2022-2023 | Ponvory |
| Ani Pharmaceuticals, INC. | $62.84 | 2023-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $62.10 | 2023 | Gammagard |
| Vanda Pharmaceuticals INC. | $46.59 | 2024-2025 | Ponvory |
| Scilex Pharmaceuticals INC. | $45.81 | 2024 | |
| Averitas Pharma INC. | $39.55 | 2023 | Qutenza |
| Octapharma USA, INC. | $38.30 | 2023-2024 | Panzyga |
| Alnylam Pharmaceuticals INC. | $29.99 | 2023 | Onpattro |
| Banner Life Sciences, LLC | $29.72 | 2024 | |
| Sumitomo Pharma America, INC. | $23.57 | 2023 | Aptiom |
| Boston Scientific Corporation | $22.87 | 2023 | |
| Greenwich Biosciences, INC. | $21.37 | 2020 | |
| Aquestive Therapeutics, INC. | $21.19 | 2022 | |
| Horizon Therapeutics Plc | $21.04 | 2023 | Uplizna |
| Impel Pharmaceuticals INC. | $20.09 | 2023 | Trudhesa |
| Grt US Holding, INC. | $18.94 | 2022 | |
| Corium, LLC | $17.05 | 2023 | Adlarity |
| Life Molecular Imaging LTD | $15.97 | 2023 | Neuraceq |
| Almatica Pharma LLC | $15.63 | 2023 | Gralise |
| Globus Medical, INC. | $15.07 | 2025 | Senza |
| Currax Pharmaceuticals LLC | $12.94 | 2020 | |
| Mallinckrodt Hospital Products INC. | $12.54 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.